Teladoc Health (NYSE:TDOC) Shares Gap Up Following Strong Earnings

Key Points

• Teladoc beat quarterly expectations: Revenue reached $605.1 million versus the $588.1 million consensus, while its loss of $0.15 per share was narrower than the expected $0.22 loss.
• Shares jumped from $6.88 to an opening price of $7.92 after the results, although the company remains unprofitable and revenue declined 3.4% year over year.
• Analyst sentiment remains cautious: Management raised full-year 2026 GAAP EPS guidance, but Teladoc has a consensus “Hold” rating and an average price target of $7.57.

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $6.88, but opened at $7.92. Teladoc Health shares last traded at $8.5020, with a volume of 4,184,026 shares traded.

The health services provider reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.15%. The company had revenue of $605.10 million for the quarter, compared to the consensus estimate of $588.14 million. During the same period in the prior year, the company posted ($0.28) EPS. The company's revenue was down 3.4% compared to the same quarter last year.

Trending Headlines about Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported third-quarter revenue of $605.1 million, ahead of the approximately $588 million analyst consensus, while its loss of $0.15 per share was narrower than the expected $0.22–$0.23 loss. The company’s year-over-year loss also improved from $0.21–$0.28 per share in the prior-year period. Teladoc Health Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised its full-year 2026 GAAP EPS guidance, giving investors greater confidence that cost controls and operating improvements may continue to reduce losses. Teladoc Stock Rallies After Double Beat; Lifts FY26 GAAP EPS Outlook
• Positive Sentiment: BetterHelp insurance revenue reached $32 million, providing a potentially important growth channel as Teladoc works to stabilize its broader consumer health business. Teladoc: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Stifel Nicolaus raised its price target from $5.50 to $6.50 but maintained a “hold” rating. Needham also reaffirmed its “hold” rating, suggesting analysts see limited near-term upside after the rally.
• Neutral Sentiment: The stock moved above its 200-day moving average, a technical development that may attract momentum-focused investors, although it does not change the company’s underlying fundamentals. Teladoc Shares Cross Above 200-Day Moving Average
• Negative Sentiment: Revenue declined approximately 3.4% year over year, and Teladoc remains unprofitable, reporting a $26.9 million net loss. Fourth-quarter revenue guidance of roughly $569 million to $615 million is also below or near some analyst expectations, limiting the bullish impact of the earnings beat. Teladoc Provides Fourth-Quarter and Full-Year 2026 Guidance

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Citigroup decreased their price target on shares of Teladoc Health from $11.00 to $7.50 and set a "neutral" rating for the company in a research note on Monday, August 3rd. Stifel Nicolaus increased their target price on shares of Teladoc Health from $5.50 to $6.50 and gave the stock a "hold" rating in a report on Thursday. Bank of America raised their target price on shares of Teladoc Health from $9.00 to $10.50 and gave the company a "buy" rating in a research report on Tuesday, July 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Teladoc Health in a research report on Thursday. Finally, Canaccord Genuity Group lowered their price target on shares of Teladoc Health from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $7.57.

Insider Transactions at Teladoc Health

In related news, CEO Charles III sold 17,805 shares of the firm's stock in a transaction on Friday, September 11th. The stock was sold at an average price of $6.10, for a total value of $108,610.50. Following the transaction, the chief executive officer owned 465,535 shares in the company, valued at approximately $2,839,763.50. This trade represents a 3.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Allworth Financial LP bought a new stake in Teladoc Health in the 2nd quarter valued at about $25,000. Twin Lakes Capital Management LLC purchased a new stake in Teladoc Health during the second quarter valued at about $26,000. Nykredit A S bought a new position in Teladoc Health during the second quarter worth about $27,000. EFG International AG bought a new position in Teladoc Health during the second quarter worth about $35,000. Finally, Public Employees Retirement System of Ohio bought a new position in Teladoc Health during the second quarter worth about $46,000. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health Price Performance

The stock has a market cap of $1.56 billion, a PE ratio of -8.59 and a beta of 2.14. The firm's 50 day moving average price is $6.15 and its two-hundred day moving average price is $6.46.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services and technology designed to connect patients with medical professionals remotely. Through its digital platforms, the company supports a range of healthcare needs, including general medical consultations, mental health services, specialty care, and ongoing management of chronic conditions.

Its offerings include telehealth visits with physicians and other licensed providers, behavioral health services through BetterHelp, and chronic care programs that use digital tools and clinical support to help people manage conditions such as diabetes and hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.